New hope for esophageal cancer: triple therapy enters major trial
NCT ID NCT07251062
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new combination of drugs for people with advanced or metastatic esophageal squamous cell carcinoma who have not had prior treatment. The experimental therapy includes SYS6010 (a targeted antibody-drug conjugate) plus SG001 (an immunotherapy), with or without standard chemotherapy. The trial aims to see if this combo shrinks tumors and extends survival. About 737 participants will be enrolled across multiple centers.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- SYS6010 (an antibody-drug conjugate targeting EGFR) combined with SG001 (an anti-PD-1 immunotherapy), with or without chemotherapy (5-FU or capecitabine)
- What this could lead to
- If successful, this could offer a new first-line treatment option for advanced esophageal cancer, potentially improving tumor shrinkage and survival.
- What could go wrong
- This is an early-to-mid-stage trial (phase 2/3) with no results yet. Side effects from the drug combination may be significant, and the treatment may not work better than existing therapies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new infusion drug shrink Hard-to-Treat tumors?
- Can a new drug combo shrink Hard-to-Treat tumors?
- Can a new drug rally the immune system against Hard-to-Treat cancers?
- AI biomarker may reveal who responds to esophageal cancer immunotherapy
- Can a single Protein's mutations predict esophageal cancer outcomes?
- A sponge you swallow could detect esophageal cancer before it spreads